Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease | Zendy

Stefanie Schreiber | Zendy; Walter Reinisch | Zendy; J F Colombel | Zendy; William J. Sandborn | Zendy; Daniël W. Hommes | Zendy; Anne Robinson | Zendy; B Huang | Zendy; Kathleen G. Lomax | Zendy; P Pollack | Zendy

Open Access

Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

Author(s) -

Stefanie Schreiber,

Walter Reinisch,

J F Colombel,

William J. Sandborn,

Daniël W. Hommes,

Anne Robinson,

B Huang,

Kathleen G. Lomax,

P Pollack

Publication year - 2012

Publication title -

journal of crohn s and colitis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.277

H-Index - 80

eISSN - 1876-4479

pISSN - 1873-9946

DOI - 10.1016/j.crohns.2012.05.015

Subject(s) - medicine , adalimumab , crohn's disease , placebo , subgroup analysis , charm (quantum number) , disease , surgery , gastroenterology , meta analysis , pathology , alternative medicine , physics , quantum mechanics

We examined the impact of disease duration on clinical outcomes and safety in a post hoc analysis of a remission maintenance trial with adalimumab in patients with moderate to severe CD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog